Terns Pharmaceuticals Inc (TERN)

NASDAQ
17.42
-1.92(-9.93%)
  • Volume:
    40,283
  • Bid/Ask:
    16.85/23.00
  • Day's Range:
    17.22 - 18.92

TERN Overview

Prev. Close
19.34
Day's Range
17.22-18.92
Revenue
-
Open
18.92
52 wk Range
14.58-28.36
EPS
-
Volume
40,283
Market Cap
437.47M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
113,915
P/E Ratio
-
Beta
-
1-Year Change
-
Shares Outstanding
25,113,167
Next Earnings Date
Sep 01, 2021
What is your sentiment on Terns Pharmaceuticals Inc?
or
Market is currently closed. Voting is open during market hours.

Terns Pharmaceuticals Inc News

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellSellNeutralBuySell
Technical IndicatorsStrong SellStrong SellStrong SellStrong BuyBuy
SummaryStrong SellStrong SellSellStrong BuyNeutral

Terns Pharmaceuticals Inc Company Profile

Terns Pharmaceuticals Inc Company Profile

Sector
Services
Employees
30

Terns Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and other chronic liver diseases. The Company’s NASH pipeline includes multiple single-agent and combination therapy candidates that provide opportunities to address the multifaceted nature of NASH and provide clinical benefits for patients. The Company’s TERN-101 is a liver-distributed, non-bile acid Farnesoid X Receptor (FXR) that has demonstrated a profile and improved target engagement due to its sustained FXR activation in the liver but only transient FXR activation in the intestine. Its TERN-101 is in a Phase 2a clinical trial. Its TERN-201 is an inhibitor of vascular adhesion protein-1 (VAP-1) that has demonstrated target engagement in clinical trials. The TERN-201 is in Phase 1b clinical trial. Its TERN-501 is in Phase 1a clinical trial.

Read More
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.